Oncology accounts for five trials in Trial Watch Edition 10, spanning blood cancers, lung cancer, prostate cancer and renal cell carcinoma.
Merck is testing MK 1045 directly against blinatumomab in relapsed or refractory B cell acute lymphoblastic leukaemia, while ImmunityBio is expanding ANKTIVA into first line advanced NSCLC. Molecular Partners is also opening the first DLL3 targeted alpha emitter radiopharmaceutical study, adding a third modality to an increasingly competitive DLL3 landscape.
Regeneron and Eikon are advancing further immune activation strategies through tumour localised 4 1BB costimulation and systemic TLR7 and TLR8 agonism.